Analysts Set Inari Medical, Inc. (NASDAQ:NARI) Price Target at $93.30

Shares of Inari Medical, Inc. (NASDAQ:NARIGet Rating) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $93.30.

NARI has been the topic of a number of analyst reports. BTIG Research dropped their price target on Inari Medical from $100.00 to $97.00 and set a “buy” rating on the stock in a research report on Monday, October 17th. Morgan Stanley increased their price target on shares of Inari Medical from $93.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, November 3rd. Truist Financial decreased their price objective on shares of Inari Medical from $87.00 to $80.00 and set a “hold” rating for the company in a report on Monday, October 17th. Canaccord Genuity Group increased their target price on Inari Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, September 16th. Finally, Canaccord Genuity Group lifted their target price on Inari Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, September 16th.

Insider Activity

In other Inari Medical news, CEO William Hoffman sold 55,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $81.67, for a total transaction of $4,491,850.00. Following the completion of the sale, the chief executive officer now directly owns 237,481 shares in the company, valued at approximately $19,395,073.27. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, COO Andrew Hykes sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the transaction, the chief operating officer now directly owns 130,991 shares of the company’s stock, valued at approximately $9,169,370. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO William Hoffman sold 55,000 shares of Inari Medical stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $81.67, for a total value of $4,491,850.00. Following the transaction, the chief executive officer now owns 237,481 shares in the company, valued at $19,395,073.27. The disclosure for this sale can be found here. Insiders have sold 224,192 shares of company stock valued at $17,256,616 in the last ninety days. 11.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Inari Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in shares of Inari Medical by 46.8% during the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock valued at $419,355,000 after purchasing an additional 1,475,313 shares during the period. BlackRock Inc. lifted its position in shares of Inari Medical by 18.8% in the third quarter. BlackRock Inc. now owns 5,415,796 shares of the company’s stock valued at $393,404,000 after acquiring an additional 858,266 shares in the last quarter. State Street Corp boosted its stake in shares of Inari Medical by 78.6% in the second quarter. State Street Corp now owns 1,302,857 shares of the company’s stock worth $88,581,000 after acquiring an additional 573,227 shares during the period. Vanguard Group Inc. grew its position in shares of Inari Medical by 13.4% during the first quarter. Vanguard Group Inc. now owns 3,518,646 shares of the company’s stock worth $318,930,000 after purchasing an additional 416,425 shares in the last quarter. Finally, Brown Advisory Inc. raised its stake in Inari Medical by 55.2% during the 2nd quarter. Brown Advisory Inc. now owns 1,078,093 shares of the company’s stock valued at $73,299,000 after purchasing an additional 383,507 shares during the period. Institutional investors own 84.11% of the company’s stock.

Inari Medical Price Performance

Shares of NASDAQ NARI opened at $77.93 on Friday. The stock has a market cap of $4.18 billion, a P/E ratio of -185.55 and a beta of 1.21. Inari Medical has a 1 year low of $50.50 and a 1 year high of $100.00. The firm has a 50-day moving average of $73.88 and a 200 day moving average of $71.22.

About Inari Medical

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Featured Articles

Analyst Recommendations for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.